Healthcare Equipment and Supplies
Company Overview of Saladax Biomedical, Inc.
Saladax Biomedical, Inc. develops and commercializes diagnostic blood tests for the practical delivery of personalized medicine in oncology. It offers MyCare chemotherapy exposure optimization tests, such as My5-FU, a chemotherapy used in the treatment of colorectal, breast, and head and neck cancers; MyPaclitaxel, a chemotherapy used in the treatment of breast, non-small cell lung, ovarian, and digestive tract cancers; and MyDocetaxel, a chemotherapy used in the treatment of breast cancer, as well as non-small cell lung, digestive tract, prostate, and head and neck cancers. The company also provides MyImatinib, which measures and helps physicians optimize a patient's exposure to imatinib (g...
116 Research Drive
Bethlehem, PA 18015
Founded in 2004
Key Executives for Saladax Biomedical, Inc.
Founder, President and Director
Vice President of R&D and Operations
Director of Worldwide Marketing
Compensation as of Fiscal Year 2016.
Saladax Biomedical, Inc. Key Developments
Saladax Biomedical, Inc. Announces U.S. Launch of MyImatinib Chemotherapy Exposure Optimization Test
Dec 1 14
Saladax Biomedical, Inc. announced the commercial launch of the MyImatinib(TM) test. MyImatinib is part of the Saladax line of MyCare(TM) diagnostic tests that determine a patient's exposure to chemotherapy in an effort to improve and personalize dosing. The MyCare tests are simple blood tests that provide oncologists with specific information about each patient's exposure to chemotherapy, helping the doctor to make informed decisions on drug dose adjustments, with the goals of maximizing the therapy's effectiveness and limiting its potential side effects. The MyImatinib tests will be managed through the Saladax Biomedical Laboratories (SBL), the CLIA-certified division of Saladax Biomedical. Imatinib is used in the treatment of multiple cancers, and is marketed in the United States by Novartis as Gleevec(R). MyImatinib joins the Saladax portfolio of tests that currently include My5-FU(TM), MyPaclitaxel(TM) and MyDocetaxel(TM). The MyCare tests are designed to provide oncologists with accurate, convenient and reliable information regarding Imatinib exposure levels.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries